Protein Therapeutics to Prevent Heart Failure Post Myocardial Infarction

预防心肌梗塞后心力衰竭的蛋白质疗法

• 批准号: 8020951
• 负责人: John C Burnett
• 金额: $ 70.28万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8020951
• 关键词: Acute myocardial infarction; Address; American Heart Association; Basic Science; Biology; Brain natriuretic peptide; Cardiac; Cardiac Myocytes; Cells; Chronic; Clinical; Clinical Research; Clinical Trials Data Monitoring Committees; Data; Functional disorder; Future; Health; Healthcare; Heart Injuries; Heart failure; Human; Incidence; Instruction; Kidney; Morbidity - disease rate; Myocardial; Myocardial Infarction; Outcome; Peptides; Prevalence; Prevention; Property; Reporting; Research; Research Personnel; Safety; Sample Size; Scientist; Site; Specialized Center; Structure; Syndrome; Therapeutic; Translational Research; Translations; base; cost; efficacy trial; follow-up; human study; meetings; mortality; novel; novel therapeutic intervention; peptide B; prevent; programs; repaired; therapeutic protein

DESCRIPTION (provided by applicant): The broad objective of this application is to establish that the endogenous cardiac peptide B-type natriuretic peptide (BNP) is a novel and efficacious protein therapeutic for human acute myocardial infarction (AMI) to preserve myocardial structure and function reducing ultimately the burden of human heart failure (HP). This highly translational research builds upon ongoing basic and clinical research pursued by the applicants and currently supported by HL83231 (Cardiac Peptides in Myocardial Infarction). Our application specifically takes advantage of the cardioprotective properties of this small and endogenous myocardial peptide in protecting the heart from injury and promoting cardiac repair. Our therapeutic strategy is based upon the emerging biology of BNP, which goes beyond renal actions and includes direct actions on cardiomyocytes and non-myocyte cardiac cells. The Specific Aims are as follows: Aim 1: To collect clinical outcome data beyond the 30 days follow up in the pilot human study supported by HL83231 so as to use this data to calculate sample size and power calculation for the multicenter "Prevention of Post Myocardial Infarction Heart Failure Safety and Efficacy Trial" to be supported by the P50 program. Aim 2: Organize the Scientific Advisory Board and Steering Committee consisting of both scientists and clinical experts to draft the plan for the multicenter "Prevention of Post Myocardial Infarction Heart Failure Safety and Efficacy Trial." We will also organize the Data and Safety Monitoring Board (DSMB). Aim 3: Engage a clinical research organization (CRO) to begin plans for site recruitment and regulatory management of the proposed multicenter "Prevention of Post Myocardial Infarction Heart Failure Safety and Efficacy Trial" that will be supported by the F50 program. Aim 4: To engage the FDA in amending our investigator held IND for the use of BNP in human myocardial infarction to include our multicenter "Prevention of Post Myocardial Infarction Heart Failure Safety and Efficacy Trial" to be supported by the P50 program. We believe that our proposal meets the objectives of the C-TRIF P20 Program and accelerates translation of promising new therapeutic interventions such as BNP for AMI to reduce the burden of future HF. RELEVANCE (See instructions): Chronic heart failure (CHF) is a clinical syndrome with significant mortality and morbidity despite recent advances in the understanding of the pathophysiology and treatment. The latest figures from the American Heart Association reports a prevalence of 5 million with incidence of 550,000 cases, annual mortality of 52,000 and a total cost of 28 billion dollars in healthcare expense per year in the US. This research will aid in addressing this health challenge.

描述(由申请人提供)： 本应用的主要目的是确定内源性心脏多肽B型利钠肽(BNP)是一种治疗人类急性心肌梗死(AMI)的新型有效蛋白质，以保护心肌结构和功能，最终减轻人类心力衰竭(HP)的负担。这项高度翻译的研究建立在申请者正在进行的基础和临床研究的基础上，目前由HL83231(心肌梗塞中的心脏肽)支持。我们的应用特别利用了这种小的内源性心肌肽在保护心脏免受损伤和促进心脏修复方面的心脏保护特性。我们的治疗策略是基于BNP的新兴生物学，它超越了肾脏的作用，包括对心肌细胞和非心肌细胞的直接作用。具体目标如下：目标1：收集HL83231支持的先导性人体试验中30天随访后的临床结果数据，以便使用这些数据计算P50计划支持的多中心“预防心肌梗塞后心力衰竭安全性和有效性试验”的样本量和功率计算。目的2：组织由科学家和临床专家组成的科学咨询委员会和指导委员会，为多中心的“预防心肌梗死后心力衰竭安全性和有效性试验”起草计划。我们还将组建数据和安全监测委员会(DSMB)。目标3：聘请临床研究组织(CRO)开始为F50计划支持的拟议多中心“预防心肌梗死后心力衰竭安全性和有效性试验”的现场招聘和监管管理计划。目的4：让FDA参与修订我们的研究人员持有的IND关于BNP在人类心肌梗死中的使用，将我们的多中心“预防心肌梗塞后心力衰竭安全性和有效性试验”纳入P50计划支持的多中心试验。我们相信，我们的建议符合C-TRIF P20计划的目标，并加速了有希望的新治疗干预措施的转化，如用于急性心肌梗死的脑钠素，以减轻未来心衰的负担。相关性(参见说明书)：慢性心力衰竭(CHF)是一种临床综合征，具有显著的死亡率和发病率，尽管最近在病理生理和治疗方面取得了进展。美国心脏协会的最新数据显示，美国的患病率为500万，发病率为55万例，年死亡率为5.2万，每年的医疗费用总额为280亿美元。这项研究将有助于应对这一健康挑战。

项目成果

Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study.

• DOI: 10.1136/hrt.2008.153916
• 发表时间: 2009-08
• 期刊: Heart (British Cardiac Society)
• 作者: Chen HH;Martin FL;Gibbons RJ;Schirger JA;Wright RS;Schears RM;Redfield MM;Simari RD;Lerman A;Cataliotti A;Burnett JC Jr
• 通讯作者: Burnett JC Jr